| 发明名称 | Method of treating coronary artery disease by administering FGF-9 | ||
| 摘要 | The present invention is directed to a method for treating a human patient for coronary artery disease, comprising administering into at least one coronary vessel of said patient a safe and angiogenically effective dose of a recombinant FGF-9 of SEQ ID NO:13, or an angiogenically active fragment or mutein thereof. The invention is also directed to a method for inducing angiogenesis in the heart of a patient, comprising administering into at least one coronary vessel of a human patient in need of coronary angiogenesis a therapeutically effective amount of a recombinant FGF-9 of SEQ ID NO:13, or an angiogenically active fragment or mutein thereof. | ||
| 申请公布号 | US9149507(B2) | 申请公布日期 | 2015.10.06 |
| 申请号 | US201314099143 | 申请日期 | 2013.12.06 |
| 申请人 | Novartis Vaccines and Dignostics, Inc. | 发明人 | Whitehouse Martha J.;Kavanaugh W. Michael |
| 分类号 | A61K38/18;C07K14/50 | 主分类号 | A61K38/18 |
| 代理机构 | Alston & Bird LLP | 代理人 | Alston & Bird LLP |
| 主权项 | 1. A method for treating a human patient for coronary artery disease, comprising administering into one or more coronary vessels in a human patient in need of treatment for coronary artery disease a therapeutically effective amount of a recombinant fibroblast growth factor (FGF) having the sequence set forth in SEQ ID NO:13. | ||
| 地址 | Emeryville CA US | ||